Entrada Therapeutics (TRDA) Stock
Biotech company developing technology to deliver drugs inside cells. Here's the price, business snapshot, and what's worth knowing about Entrada Therapeutics in September 2026.
Entrada Therapeutics, Inc. (ticker TRDA) is a biotechnology company developing technologies aimed at delivering large-molecule therapies into cells. The company's work focuses on enabling intracellular delivery of oligonucleotides, proteins and other biologics — a technical challenge that could broaden the applicability of nucleic‑acid and protein medicines. With a market capitalisation of $241.92M, Entrada's value drivers are likely to include pipeline progress, partnerships and any validation of its delivery platform. Investing in small‑cap biotechs carries higher risk: development timelines can be long, R&D spending is typically substantial, outcomes may be binary and equity dilution is common. This summary is for general educational purposes only and does not constitute financial advice. Consider company filings, cash runway, clinical or regulatory milestones and consult a regulated financial adviser to assess whether TRDA fits your risk profile and investment horizon.
About This Stock
ENTRADA THERAPEUTICS INC
TRDA
Current Price
$6.80
Potential 12 Month Profit
222.00%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
TRDA
Market Cap
$264.77M
Potential 12 Month Profit
222.00%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Entrada Therapeutics stock, expecting its value to rise significantly.
Financial Health
Entrada Therapeutics is generating moderate revenue and cash flow, but faces challenges in growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform Potential
A delivery platform could expand which diseases are treatable and create licensing opportunities, though technical and clinical validation remain crucial.
Early-stage Programme
Progress in preclinical or early clinical programmes can be catalytic for valuation, but outcomes are uncertain and timelines can be lengthy.
Partnering & Licensing
Collaborations can de‑risk development and provide funding; however, deal terms, milestones and future financing needs are important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.